Ogeda
CompanyBelgium
Ogeda develops one asset, approved (fezolinetant in hot flashes). Mostly small molecule acting on TACR3; based in Belgium.
- 1
- Asset
- Furthest stage
- Approved
- 1
- Trial
- 2
- Signals
Pipeline
1Blocks neurokinin 3 receptors to reduce menopausal hot flashes.
Approved, Small molecule, TACR3, hot flashes, menopause
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Signals2
- Similar companies6